Latin America Peptic Ulcer Drugs Market

Latin America Peptic Ulcer Drugs Market Size (2024 to 2029)

The Latin America peptic ulcer drugs market size is estimated to reach USD 0.46 billion by 2029. In 2024, the market was sized at USD 0.39 billion, at a CAGR of 3.51% during 2024 - 2029.

A peptic ulcer is a breakage in the inner surface of the stomach or the upper part of the intestine in the gastrointestinal tract. Ulcers form when the protective wall of the intestine or stomach is broken.

The market for peptic ulcer drugs in Latin America is booming due to the increasing prevalence of chronic diseases and cancer and the growing demand for cell therapies to treat these diseases. Further, the increasing patient preference for taking medication over surgical procedures is driving the growth of the Latin American market during the forecast period.

In addition, the increasing attention to research and development activities and the growing number of generic manufacturers of peptic ulcer drugs in the region is expected to provide promising opportunities for many international companies. Some of the significant factors driving the Latin America peptic ulcer drug market are a significant increase in the group of patients infected with H. pylori, technological advancements in peptic ulcer therapies, and stressed lifestyles.

There is an increasing number in the geriatric population, improved healthcare diagnostic, easy availability of drugs for self-diagnosed treatment, favorable government initiatives, and overuse of peptic ulcer disease. Pain relievers/ anti-inflammatory drugs are the engine of this disease growth in the Latin American peptic ulcer drug market. Moreover, lifestyle changes such as stress, spicy diet, and increased alcohol use are believed to help in the growth of the Latin America peptic ulcer drug market.

However, the wide availability of generic drugs, the low adherence to treatment by patients in some developing countries, and the side effects associated with the use of drugs such as nausea, impaired taste perception would negatively affect the growth of Latin American peptic ulcer drugs market. Additionally, low pipeline productivity due to heavy taxes on the import of medical raw materials, and changes in drug pricing policies are not regulated, these factors are expected to hamper the growth of the Latin America peptic ulcer drug market over the next few years.

This research report on the Latin America peptic ulcer drugs market has been segmented and sub-segmented into the following categories:

By Drug Type:

• Proton Pump Inhibitors (PPIs)
• Anti-Histamines
• H2 Antagonists
• Antacids
• Antibiotics
• Others

By Ulcer Type:

• Gastric Ulcers
• Duodenal Ulcer
• Esophageal Ulcer

By Country:

• Brazil
• Argentina
• Chile
• Mexico
• Rest of Latin America

Mexico is expected to continue to hold the largest 41.5% share of the Latin America peptic ulcer market owing to an increase in the use of nonsteroidal anti-inflammatory drugs (NSAIDs) eg aspirin. Brazil holds the second-highest contribution to Latin America peptic ulcer market revenue share, followed by Argentina market owing to the immediate availability of a variety of treatment options for peptic ulcers in the region. Brazil's market share will grow owing to the largest population in the region.

Mexico dominated the Latin America peptic ulcer drug market share in 2020, and this trend is also expected to continue during the forecasted period. The growing government initiatives for the proper use of nonsteroidal anti-inflammatory drugs (NSAIDs) and better hospital facilities are factors driving the growth of the peptic ulcers drugs market in Mexico.

Other Latin American countries are also expected to have good market growth owing to the growing interest of international companies to build pharmaceutical companies at low costs and increasing medical tourism. Peru, Chile, and Puerto Rico collectively hold a market share of approximately 25%, while the rest of Latin America had the lowest market share and this is expected to remain the same during the projected period.

KEY MARKET PLAYERS:

Novartis AG, Daiichi Sankyo Company Limited, Acetelion Ltd, Boehringer Ingelheim, Sanofi S.A., Astra Zeneca, Ranbaxy Laboratories Limited, Inc., Takeda Pharmaceuticals Company Limited, Pfizer Inc., Helicure AB, and Eumedica Pharmaceuticals are some of the companies currently dominating the Latin America peptic ulcer drugs market and profiled in this report.